1-(diethylamino)-3-methyl-4-pyrido[1,2-a]benzimidazolecarbonitrile is a chemical compound with the molecular formula C18H20N4. It's a complex molecule with a specific structure that makes it interesting for research purposes.
**Here's a breakdown:**
* **Structure:** The name itself hints at the structure:
* **Pyrido[1,2-a]benzimidazole:** This is a fused ring system containing a pyridine ring (six-membered ring with nitrogen) and a benzimidazole ring (fused benzene and imidazole rings).
* **1-(diethylamino):** A diethylamino group (-N(CH2CH3)2) is attached at the 1 position of the benzimidazole ring.
* **3-methyl:** A methyl group (-CH3) is attached at the 3 position of the benzimidazole ring.
* **4-carbonitrile:** A cyano group (-CN) is attached at the 4 position of the benzimidazole ring.
**Importance in Research:**
This specific compound is likely of interest due to its potential **pharmacological properties**. Here are some reasons why it could be researched:
* **Targeting Specific Biological Pathways:** The unique structure of the molecule might allow it to bind to and modulate specific proteins or enzymes involved in cellular processes. This could lead to its use as a drug or tool for studying biological pathways.
* **Antimicrobial Activity:** Some benzimidazole derivatives have shown antimicrobial activity. This compound might exhibit similar properties against bacteria, fungi, or viruses.
* **Anti-Cancer Activity:** The combination of a benzimidazole core and other functional groups might lead to anticancer activity.
* **Neuroprotective Properties:** Benzimidazole derivatives have been investigated for their potential neuroprotective effects. This compound might show activity in preventing neuronal damage.
**It's important to note:**
* **Research Stage:** The information provided is based on general knowledge about chemical structures and their potential uses. Without specific details about the research being conducted, it's impossible to know the precise reasons for studying this particular compound.
* **Safety:** Any chemical compound should be handled with care. It's crucial to follow appropriate safety procedures and protocols in research.
**To learn more about the specific research on this compound, you would need to consult research publications or databases where this compound might be listed.**
ID Source | ID |
---|---|
PubMed CID | 679573 |
CHEMBL ID | 1488485 |
CHEBI ID | 114717 |
Synonym |
---|
CBMICRO_035057 |
OPREA1_610176 |
AKOS002169839 |
OPREA1_351328 |
BIM-0034927.P001 |
1-diethylamino-3-methyl-benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile |
smr000433717 |
MLS000768983 |
CHEBI:114717 |
STK842826 |
1-(diethylamino)-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile |
HMS2797E05 |
CHEMBL1488485 |
XONJKKJNPBFWFF-UHFFFAOYSA-N |
cl-2082 |
Q27196122 |
1-(diethylamino)-3-methyl-4-pyrido[1,2-a]benzimidazolecarbonitrile |
1-diethylamino-3-methyl-benzo(4,5)imidazo(1,2-a)pyridine-4-carbonitrile |
294850-34-3 |
DTXSID101323515 |
Class | Description |
---|---|
pyridobenzimidazole | An organic heterotricyclic compound that is any benzimidazole ortho-fused to a pyridine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 3.9811 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 5.6234 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 12.5893 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 8.9125 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 7.3078 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
DNA polymerase beta | Homo sapiens (human) | Potency | 89.1251 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
snurportin-1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 3.5481 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |